Indian dac generics were launched in December 2015, but sublicenses between BMS and 4 indian dac producers (Natco, Hetero, Emcure, Cipla) and medicine patent pool was announced only at 20 January 2016 – http://www.medicinespatentpool.org/the-medicines-patent-pool-signs-first-sub-licences-for-hepatitis-c-medicine-daclatasvir/

Thank you Dr Freeman but you just repeated what Serg had said in his initial post…

I really doubt that it is a typo as it’s been already 4 days since the announcement was out. They would’ve already changed it to Ledifos. But let’s see…
Ledisof mentioned 3 times in the announcement – so 3 times typo) 2nd biggest pharm company in India

Wasn’t it supposed to be Ledifos and not Ledisof…?

http://www.business-standard.com/article/pti-stories/hetero-gets-dcgi-approval-to-market-hepatitis-c-drug-115120800640_1.html

It says on Ledifos bottle that it is only for sale in India, so the same as Ledisof (for Indian patients only) – so really don’t understand why hetero now needs two different brand names for the same product to be manufactured for Indian patients only…?
Lisof is for Nepali market only…

Already asked Dr. Freeman. He shoul be speaking with the lab tomorrow so to make sure the results are out this week. Thanks to Dr.